Please assess the completion status of the following clinical trial:

Trial Title: Alternative in Beta Blocker Intolerance: The ABBI Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 21~* Male or female who is post-menopausal or not pregnant and using an approved contraceptive regimen~* Previous beta blocker use and intolerant of beta blocker~Exclusion Criteria:~* Systolic blood pressure \< 100 mmHg unless another blood pressure medication is stopped at the time of study entry~* Hospitalized for heart failure within the past 4 weeks~* Bradycardia with a heart rate \< 60~* Heart block greater than first degree~* History of sick sinus syndrome (unless a permanent pacemaker is in place)~* History of severe hepatic or renal dysfunction; serum Creatinine \> 2.0 or Amylase \> 3x normal~* Use of CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)~* Ingestion of investigational drug within the past 30 days

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: EXPERIMENTAL): Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.

Based on this trial design, predict the completion outcome and termination type (if applicable).